Results
Evaluation of E/C/F/TAF switch followed by ledipasivir-sofosbuvir antiviral HCV therapy in HIV-HCV co-infection
Learn MoreResults
Prospective investigation of the relationship between food insecurity and health and behavioural outcomes in HIV-HCV co-Infection: Clues for prevention interventions. A food security & HIV-HCV sub-study of the Canadian Co-Infection Cohort (CTN 222)
Learn MoreResults
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals.
Learn MoreTerminated
Open label, dose escalating phase I/II study of TG4040 (MVA-HCV) in patients chronically infected with hepatitis C virus (Genotype I) who relapsed from previous pegylated interferon/ribavirin treatment
Learn MoreEnrolling
A prospective clinical cohort of HIV and hepatitis C virus co-infected patients
Learn MoreResults
Trial of Citalopram for the Prevention of Depression
Learn MoreCompleted
Acceptability and implications of the rapid hepatitis C virus screening test among provincial prison inmates in Quebec: A pilot study
Learn MoreResults
A pilot, prospective, open-label study to evaluate the safety and efficacy of Kaletra® monotherapy in HIV/HCV co-infected subjects
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
